Trial for the HER2+ or HER2++ with advanced bc or mets
 

Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

This study is currently recruiting patients.
Verified by Fresenius Biotech GmbH April 2006

Sponsored by:Fresenius Biotech GmbH

Information provided by:Fresenius Biotech GmbH

ClinicalTrials.gov Identifier:NCT00351858
http://www.clinicaltrials.gov/html/images/arrow2.gif Purpose

The purpose of this study is to determine the safety and efficacy of the investigational trifunctional anti-Her-2/neu x anti-CD3 antibody ertumaxomab as treatment for hormone therapy refractory Her-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer